SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpirax-Sarco Regulatory News (SPX)

Share Price Information for Spirax-Sarco (SPX)

Share Price is delayed by 15 minutes
Get Live Data
6,785.00    90.00 (1.34%)
Bid:
6,785.00
Ask:
6,795.00
Spread: 10.00 (0.147%)
Market Cap: £5.01b
SPX Live PriceLast checked at - London Stock Exchange

Intraday Spirax-Sarco Share Chart

Interim Management Statement

7 Nov 2013 07:00

RNS Number : 4013S
Spirax-Sarco Engineering PLC
07 November 2013
 



 

 

News Release

 

Thursday 7th November 2013

INTERIM MANAGEMENT STATEMENT

 

Strong financial performance against challenging market backdrop

 

Spirax-Sarco Engineering plc, the world leader in the control and efficient use of steam and in peristaltic pumping, issues the following Interim Management Statement in respect of the period from 1st July 2013 to 6th November 2013.

 

Trading

In the four-month period ending 31st October, organic sales were 4% higher than the prior year, as sales growth continued at the same pace as the first half-year. Asia Pacific sales growth was higher in the period, reflecting the benefit of project shipments from orders booked in the first half and continued strong growth in China. Sales grew modestly in each of our EMEA and Americas segments, similar to the rates of growth in the first half. Demand remained soft in North America but the lower sales were more than offset by growth in Latin America. Our Watson-Marlow pumps business faced a particularly difficult comparison due to several large, non-repeating wastewater treatment and mining projects that shipped in the period last year.

 

Recent improvements in global economic conditions have had little overall impact on our markets. Conditions in our mature markets in Europe and North America remain challenging - routine customer maintenance spending has continued stable and resilient but higher value energy saving and plant improvement expenditures are at low levels. Conditions are quite varied in our emerging markets, where we have seen improvement in Southeast Asia and Eastern Europe but recent weakening of conditions in Latin America.

Currency movements have been favourable so far this year, adding less than 2% to sales growth. However, the recent strength of sterling and weakness in some emerging market currencies will, if maintained, erode this favourable currency gain to around 1% for the full year.

 

Our trading performance in the four months ended 31st October 2013 was in line with our expectations. Efficiency improvements in our European manufacturing operations and the cost savings from last year's restructuring in our European sales companies are reflected in higher Group operating margins that remain comfortably ahead of the prior year. As noted previously, our normal seasonal profit bias towards the second half-year was exaggerated in 2012 and we expect that 2013 will revert to a normal first-half/second-half profile.

 

Financial position

Our balance sheet and cash flow remain strong with a net cash balance of £22 million at 31st October 2013, having paid the special dividend of £78 million in July. The interim dividend of 18p per share in respect of 2013, totalling £14 million, will be paid on 8th November 2013. There has been no material change in the financial position of the Group during the period and the principal risks and uncertainties remain as set out on pages 55 to 59 of the 2012 Annual Report. Under new Corporate Governance rules, we are in the process of tendering the Group audit in respect of the period commencing with the 2014 audit and expect to reach a conclusion by the end of this year.

 

Outlook

Our markets tend to broadly mirror general economic activity and rates of industrial production, which we expect to exhibit continued low levels of growth for the balance of this year. Our focus remains on generating our own growth through our strategic priorities of expanding our presence in emerging markets, delivering a broader range of energy saving and plant improvement solutions, and growing market share. Despite sluggish markets and erosion in favourable currency movements, the Board remains confident that the Group will make good progress in 2013.

 

 

Enquiries:

Mark E Vernon, Chief Executive

David Meredith, Director Finance

Tel: 01242 535234

 

Note: References to profit are to adjusted profit that excludes the amortisation of acquisition-related intangible assets, acquisition and disposal costs, and contingent consideration fair value adjustments, together with the tax effects on these items.

 

 

 

 

About Spirax Sarco

Spirax-Sarco Engineering plc is the world leader in both steam system management and peristaltic pumping. The Company provides a broad range of fluid control products, engineered packages, site services and systems expertise for its diverse range of over 100,000 industrial and institutional customers. The Company helps its customers to optimise production capacity, reduce energy costs and emissions, improve product quality and enhance the safety of their operations. Spirax Sarco is headquartered in Cheltenham, England, has strategically located manufacturing plants around the world and employs approximately 4,700 people, of whom around 1,300 are direct sales and service engineers. Its shares have been listed on the London Stock Exchange since 1959 (symbol: SPX). Further information can be found at www.spiraxsarcoengineering.com 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBRBDBCDGBGXL
Date   Source Headline
1st Mar 20227:30 amRNSChange of Director Details
31st Jan 20227:00 amRNSCompletion of the acquisition of Cotopaxi
24th Jan 20227:00 amRNSAcquisition to accelerate digital strategy
17th Nov 20217:00 amRNSTrading Update
15th Nov 20211:54 pmRNSDirector/PDMR Shareholding
11th Aug 20214:46 pmRNSCorrection to Dividend Record Date in News Release
11th Aug 20217:00 amRNS2021 Half Year Results
3rd Aug 20217:00 amRNSBoard Changes
22nd Jun 20217:00 amRNSDirector/PDMR Shareholding
17th Jun 20217:00 amRNSNew Sustainability Targets Launched
4th Jun 20218:12 amRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSNews Release - Investor Seminar
12th May 20214:53 pmRNSResult of AGM
12th May 20217:00 amRNSAGM TRADING UPDATE
10th May 20219:16 amRNSDirector/PDMR Shareholding
12th Apr 202111:44 amRNSDirector/PDMR Shareholding
26th Mar 20218:12 amRNSDirector/PDMR Shareholding
10th Mar 20217:00 amRNS2020 Preliminary Results
9th Mar 20218:30 amRNSBoard Appointment
7th Jan 20214:05 pmRNSDirector/PDMR Shareholding
14th Dec 202010:00 amRNSDirector/PDMR Shareholding
18th Nov 20207:00 amRNSTrading Update
9th Nov 20209:00 amRNSBoard Appointments
21st Oct 20209:21 amRNSChange of Director Details
12th Oct 20205:08 pmRNSDirector/PDMR Shareholding
12th Oct 202010:00 amRNSDirectorate Change
14th Sep 20208:00 amRNSChief Financial Officer
18th Aug 20204:19 pmRNSDirector/PDMR Shareholding
12th Aug 20207:00 amRNS2020 Half Year Results
6th Aug 20208:00 amRNSAdditional Listing
28th Jul 202012:24 pmRNSSection 430(2b) Companies Act - Nimesh Patel
23rd Jul 20207:30 amRNSChange of Director Details
22nd Jun 20203:39 pmRNSChange of Director Details
22nd Jun 20202:45 pmRNSDirector/PDMR Shareholding
20th May 20209:00 amRNSChange of Director Details
13th May 20204:32 pmRNSResult of AGM
13th May 20207:00 amRNSAGM Statement - Trading Update
28th Apr 202011:30 amRNSDisclosure of Rights attached to Equity Shares
24th Apr 20208:59 amRNSAGM Alternative Arrangements
8th Apr 202010:33 amRNSSection 430(2B) Companies Act 2006 Statement
3rd Apr 202011:14 amRNSDirector/PDMR Shareholding
2nd Apr 20208:00 amRNSSpirax Sarco appoints next Chief Financial Officer
30th Mar 20208:30 amRNSChange of Director Details
13th Mar 20209:48 amRNSDirector/PDMR Shareholding
12th Mar 202012:00 pmRNSDirector/PDMR Shareholding
11th Mar 20207:05 amRNSBoard Change
11th Mar 20207:00 amRNS2019 Preliminary Results
7th Feb 20205:35 pmRNSDirector Declaration
13th Nov 20197:00 amRNSTrading Update
10th Sep 20193:30 pmRNSChange of Director Details

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.